FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Fulcrum Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$3.70+0.05 (+1.37%)
Close on Oct 19, 2026
- Market cap
- $282.18M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$5.29 (−58.84%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Fulcrum Therapeutics, Inc. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$66.14M.
Revenue
$0
-100.0% vs. a year earlier
Operating income
-$96.05M
TTM Q2 2026
Free cash flow
-$66.14M
TTM Q2 2026
EPS, diluted
-$1.18
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $282.18M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.91
- Dividend yield
- –
- Free cash flow yield
- -23.44%
Fundamentals
- Revenue
- $0
- Net income
- -$85.00M
- EPS, diluted
- -$1.18
- Free cash flow
- -$66.14M
- Book value per share
- $4.07
- Diluted shares
- 76M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$96.05M
Net income
-$85.00M
EPS, diluted
–
Free cash flow
-$66.14M
Reported periodTrailing twelve months